Celtic could plunder Jose Mourinho s new side for #1
May 12, 2021
The likelihood is that Celtic will be in the market for a new goalkeeper, and they might just be ringing up Jose Mourinho.
The ‘Special One’ was tentatively discussed as a candidate to replace Neil Lennon. It was pie in the sky stuff, and the Bhoys dressing room probably dodged a bullet there. At Roma, however, he can rebuild his reputation as a winner. The underwhelming capital city side have needed a ruthless streak. Under Mourinho, they get that quality in spades.
However, that’s not what’s relevant to Celtic. What is relevant is their Swedish international goalkeeper, Robin Olsen. Second choice to Jordan Pickford on loan at Everton, Il Romanista are suggesting that Olsen could be available for anywhere between £4.3m and £5.2m.
JONATHAN Gould believes whoever Celtic appoint as their new manager has to make signing a top class keeper his No1 priority this summer if the Parkhead club are to reclaim the Scottish title from Rangers next season. Speculation has been rife about who will replace Neil Lennon in recent weeks and Eddie Howe, the former Bournemouth and Burnley manager, looks set to be confirmed as his replacement in the coming days. However, for Gould, who helped the Glasgow club stop their city rivals from completing 10-In-A-Row at the end of his debut season in 1998, bringing in an exceptional goalie is every bit as important to their future prospects.
Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production
Lipidor AB (Nasdaq First North: LIPI)
announced today that the Company has signed a new cooperation agreement with Aurena Laboratories AB. Over a five-year period, Lipidor will invest up to SEK 15 million in the new collaboration. Under the agreement, Aurena Laboratories will establish a production unit to meet the regulatory requirements for the manufacture of Lipidor s pharmaceutical products. This will enable Lipidor to offer potential licensees the opportunity for large-scale commercial production. This is an important step towards a licensing agreement for Lipidor drug candidates, AKP01 and AKP02, for the treatment of psoriasis.